RxDoctor Payments Data

David Kraan, DO

Internal Medicine · Azle, TXNPI 1063033629

Payments from drug & device makers

$805in general payments, 2019–2025

Across 43 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$216
  • AbbVie$146
  • Echosens North America, Inc.$100
  • Lilly USA, LLC$92
  • Novo Nordisk$88
  • Inspire Medical Systems, Inc.$37
  • plus $127 from 5 others

What the payments were for

  • Food & beverage$805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$805 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$37,185
Medicare patients
99
Services billed
573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$24,160
JardianceEmpagliflozin14$19,298
FarxigaDapagliflozin Propanediol11$15,629
MounjaroTirzepatide14$14,385
Levetiracetam15$933
Amiodarone Hcl11$921
Gabapentin50$791
Albuterol Sulfate HfaAlbuterol Sulfate23$630
Losartan Potassium72$629
Rosuvastatin Calcium37$578
Levothyroxine Sodium78$556
Omeprazole23$455
Metformin Hcl ErMetformin Hcl26$446
Amlodipine Besylate56$378
Atorvastatin Calcium52$340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$24,16030 claims
AstraZenecaFarxiga$216$15,62911 claims
Lilly USA, LLCMounjaro$92$14,38514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Azle

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →